KurkinenGrouplogo

PUBLICATIONS

Kurkinen M, Daly T (2024) Survival time in Alzheimer’s disease: an overlooked measure of safety and efficacy of disease-modifying therapies. Adv Clin Exp Med, in press

Daly T, Kurkinen M (2024) Measuring our language about anti-amyloid antibodies in Alzheimer’s disease: technical, theoretical, and lay language considerations. Clin Neurol Neurosurg 241:108314

Kurkinen M (2024) Anti-amyloid therapies do not slow Alzheimer’s disease progression. Dementia Neuropsychol 17:e20230099

Kurkinen M (2023) Donanemab: Not two without a third. Add Clin Exp Med 32, 1085–1087

Kurkinen M (2023) Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med 32, 943–947

Kurkinen M, Fułek M, Fułek K, Beszłej JA, Kurpas D, Leszek J (2023) The amyloid cascade hypothesis in Alzheimer’s disease: Should we change our thinking? Biomolecules 13, 453

Kurkinen M (2022) Astrocyte glutamate transporter EAAT2 in Alzheimer dementia. Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments (Zoran Pavlovic, Ed.) Springer Nature,  Berlin, Germany, pp. 229–260

Kurkinen M, Tran L (2021) Aduhelm: The best hope for Alzheimer’s patients or the worst decision the FDA ever made? J Alzheimers Dis 84, 969-971

Kurkinen M (2021) Alzheimer’s trials: A cul-de-sac with no end in sight. Adv Clin Exp Med 30, 653-654

Kurkinen M (2018) Alzheimer’s dementia drug discovery: targeting astrocyte glutamate uptake. Conn’s Handbook of Models for Human Aging, 2nd Ed (Ronald Conn and Jeffrey Ram, Eds.) Elsevier, pp. 587-591

Kurkinen M (2017) The amyloid hypothesis is too good to be true. Alzheimers Dement Cogn Neurol 1, 1-9

PUBLICATIONS

Kurkinen M, Daly T (2024) Survival time in Alzheimer’s disease: an overlooked measure of safety and efficacy of disease-modifying therapies. Adv Clin Exp Med, in press Daly T, Kurkinen M (2024) Measuring our language about anti-amyloid antibodies in Alzheimer’s disease: technical, theoretical, and lay language considerations. Clin Neurol Neurosurg 241:108314 Kurkinen M (2024) Anti-amyloid therapies do not slow Alzheimer’s disease progression. Dementia Neuropsychol 17:e20230099 Kurkinen M (2023) Donanemab: Not two without a third. Add Clin Exp Med 32, 1085–1087 Kurkinen M (2023) Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med 32, 943–947 Kurkinen M, Fułek M, Fułek K, Beszłej JA, Kurpas D, Leszek J (2023) The amyloid cascade hypothesis in Alzheimer’s disease: Should we change our thinking? Biomolecules 13, 453 Kurkinen M (2022) Astrocyte glutamate transporter EAAT2 in Alzheimer dementia. Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments (Zoran Pavlovic, Ed.) Springer Nature,  Berlin, Germany, pp. 229–260 Kurkinen M, Tran L (2021) Aduhelm: The best hope for Alzheimer’s patients or the worst decision the FDA ever made? J Alzheimers Dis 84, 969-971 Kurkinen M (2021) Alzheimer’s trials: A cul-de-sac with no end in sight. Adv Clin Exp Med 30, 653-654 Kurkinen M (2018) Alzheimer’s dementia drug discovery: targeting astrocyte glutamate uptake. Conn’s Handbook of Models for Human Aging, 2nd Ed (Ronald Conn and Jeffrey Ram, Eds.) Elsevier, pp. 587-591 Kurkinen M (2017) The amyloid hypothesis is too good to be true. Alzheimers Dement Cogn Neurol 1, 1-9

PUBLICATIONS

Kurkinen M, Daly T (2024) Survival time in Alzheimer’s disease: an overlooked measure of safety and efficacy of disease-modifying therapies. Adv Clin Exp Med, in press Daly T, Kurkinen M (2024) Measuring our language about anti-amyloid antibodies in Alzheimer’s disease: technical, theoretical, and lay language considerations. Clin Neurol Neurosurg 241:108314 Kurkinen M (2024) Anti-amyloid therapies do not slow Alzheimer’s disease progression. Dementia Neuropsychol 17:e20230099 Kurkinen M (2023) Donanemab: Not two without a third. Add Clin Exp Med 32, 1085–1087 Kurkinen M (2023) Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med 32, 943–947 Kurkinen M, Fułek M, Fułek K, Beszłej JA, Kurpas D, Leszek J (2023) The amyloid cascade hypothesis in Alzheimer’s disease: Should we change our thinking? Biomolecules 13, 453 Kurkinen M (2022) Astrocyte glutamate transporter EAAT2 in Alzheimer dementia. Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments (Zoran Pavlovic, Ed.) Springer Nature,  Berlin, Germany, pp. 229–260 Kurkinen M, Tran L (2021) Aduhelm: The best hope for Alzheimer’s patients or the worst decision the FDA ever made? J Alzheimers Dis 84, 969-971 Kurkinen M (2021) Alzheimer’s trials: A cul-de-sac with no end in sight. Adv Clin Exp Med 30, 653-654 Kurkinen M (2018) Alzheimer’s dementia drug discovery: targeting astrocyte glutamate uptake. Conn’s Handbook of Models for Human Aging, 2nd Ed (Ronald Conn and Jeffrey Ram, Eds.) Elsevier, pp. 587-591 Kurkinen M (2017) The amyloid hypothesis is too good to be true. Alzheimers Dement Cogn Neurol 1, 1-9

TALKS

March 9, 2017, Detroit, USA Wayne State University School of Medicine, Department of Physiology Alzheimer’s drug discovery: Wo Sind die Magischen Kugeln?

June 22-24, 2017, Copenhagen, Denmark 13th World Federation of Societies of Biological Psychiatry Alzheimer’s drug discovery: targeting synaptic glutamate uptake

August 27-September 2, Naples-Florence, Italy Congress on Invertebrate Models of Human Aging Alzheimer’s drug discovery: targeting synaptic glutamate uptake

September 20, 2018, Stockport, UK The Meadows Hospital Alzheimer’s drug discovery and clinical development

September 24-25, 2018, London, UK Dementia and Dementia Care Alzheimer’s drug discovery: targeting synaptic glutamate uptake

January 30, 2019, Stockport, UK Vascular Dementia Conference Microvascular events in development of dementia

February 18-21, 2019, San Francisco, USA Alzheimer Society International Congress (ASIC) Alzheimer drugs: targeting synaptic glutamate uptake

February 21-24, 2019, Sydney, Australia 7th World Congress of Asian Psychiatry (WCAP) Alzheimer drugs: targeting synaptic glutamate uptake

November 29-30, 2019, Wroclaw, Poland 13th International Conference of Psychogeriatrics 2019: State of Art Alzheimer’s drugs: targeting synaptic glutamate uptake

RESEARCH

Handout

POSTERS

AAIC 2014 Copenhagen AAIC 2015 Washington DC AAIC 2016 Toronto

TALKS

March 9, 2017, Detroit, USA Wayne State University School of Medicine, Department of Physiology Alzheimer’s drug discovery: Wo Sind die Magischen Kugeln?

June 22-24, 2017, Copenhagen, Denmark 13th World Federation of Societies of Biological Psychiatry Alzheimer’s drug discovery: targeting synaptic glutamate uptake

August 27-September 2, Naples-Florence, Italy Congress on Invertebrate Models of Human Aging Alzheimer’s drug discovery: targeting synaptic glutamate uptake

September 20, 2018, Stockport, UK The Meadows Hospital Alzheimer’s drug discovery and clinical development

September 24-25, 2018, London, UK Dementia and Dementia Care Alzheimer’s drug discovery: targeting synaptic glutamate uptake

January 30, 2019, Stockport, UK Vascular Dementia Conference Microvascular events in development of dementia

February 18-21, 2019, San Francisco, USA Alzheimer Society International Congress (ASIC) Alzheimer drugs: targeting synaptic glutamate uptake

February 21-24, 2019, Sydney, Australia 7th World Congress of Asian Psychiatry (WCAP) Alzheimer drugs: targeting synaptic glutamate uptake

November 29-30, 2019, Wroclaw, Poland 13th International Conference of Psychogeriatrics 2019: State of Art Alzheimer’s drugs: targeting synaptic glutamate uptake

RESEARCH

Handout

POSTERS

AAIC 2014 Copenhagen AAIC 2015 Washington DC AAIC 2016 Toronto

TALKS

March 9, 2017, Detroit, USA Wayne State University School of Medicine, Department of Physiology Alzheimer’s drug discovery: Wo Sind die Magischen Kugeln?

June 22-24, 2017, Copenhagen, Denmark 13th World Federation of Societies of Biological Psychiatry Alzheimer’s drug discovery: targeting synaptic glutamate uptake

August 27-September 2, Naples-Florence, Italy Congress on Invertebrate Models of Human Aging Alzheimer’s drug discovery: targeting synaptic glutamate uptake

September 20, 2018, Stockport, UK The Meadows Hospital Alzheimer’s drug discovery and clinical development

September 24-25, 2018, London, UK Dementia and Dementia Care Alzheimer’s drug discovery: targeting synaptic glutamate uptake

January 30, 2019, Stockport, UK Vascular Dementia Conference Microvascular events in development of dementia

February 18-21, 2019, San Francisco, USA Alzheimer Society International Congress (ASIC) Alzheimer drugs: targeting synaptic glutamate uptake

February 21-24, 2019, Sydney, Australia 7th World Congress of Asian Psychiatry (WCAP) Alzheimer drugs: targeting synaptic glutamate uptake

November 29-30, 2019, Wroclaw, Poland 13th International Conference of Psychogeriatrics 2019: State of Art Alzheimer’s drugs: targeting synaptic glutamate uptake

RESEARCH

Handout

POSTERS

AAIC 2014 Copenhagen AAIC 2015 Washington DC AAIC 2016 Toronto